A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
The Indianapolis drug giant's stock (LLY) reached an intraday high of $1,061.17 in morning trading and closed at $1,059.70 on Friday, which was above the threshold of $1,057.78 needed for Lilly to ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly ...
A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback